Evidence to Support Goals:
The measurement of SMBG is a common practice of evaluating patients’ BG control at home, especially when on insulin. This helps a provider to determine opportunities to adjust insulin and reduce adverse drug events (i.e. hypoglycemia); however, a common issue is communication of SMBG between patient and caregiver.
The Mobile Diabetes Intervention Study evaluated the utilization of a mobile diabetes management tool’s effect on diabetic patients’ glycated hemoglobin levels (A1c) over a 1-year period [1]. Results demonstrated that patients enrolled in the intervention group had a reduction in A1c by 1.9%, compared with 0.7% for the control group, a difference of 1.2% (P < 0.001) over 12 months [1].
Additional studies have evaluated the integration of mobile devices into direct diabetes management and care [2-4]. A review by Russell-Minda E, et al. noted that electronic SMBGs allow for easier communication between patients and prescribers about diabetes management [2]. A pattern analysis conducted by Parkin CG, et al. demonstrated that the utilization of SMBGs allows healthcare providers to identify issues in diabetes management and make rational therapeutic adjustments based on objective data [3].
However, the limitations facing the utilization of diabetes monitoring apps are the reliance on patients inputting data manually, which may reduce adherence, as noted by Ciemins E, et al [4]. It must be noted that further studies are needed to determine the use of applications to reduce microvascular and macrovascular complications of diabetes [2, 4].
Lastly, a recent review conducted via iMedicalApps evaluated the use of Diabetes Buddy in managing patients with Adult Type 1 Diabetes. The study investigated the utilization of the application as an adjunctive tool to help manage diabetes. Results demonstrated that there was a significant decrease in A1c in the intervention group over the control group who did not use the app [5].
Evidence to Support Goals:The measurement of SMBG is a common practice of evaluating patients’ BG control at home, especially when on insulin. This helps a provider to determine opportunities to adjust insulin and reduce adverse drug events (i.e. hypoglycemia); however, a common issue is communication of SMBG between patient and caregiver.The Mobile Diabetes Intervention Study evaluated the utilization of a mobile diabetes management tool’s effect on diabetic patients’ glycated hemoglobin levels (A1c) over a 1-year period [1]. Results demonstrated that patients enrolled in the intervention group had a reduction in A1c by 1.9%, compared with 0.7% for the control group, a difference of 1.2% (P < 0.001) over 12 months [1].Additional studies have evaluated the integration of mobile devices into direct diabetes management and care [2-4]. A review by Russell-Minda E, et al. noted that electronic SMBGs allow for easier communication between patients and prescribers about diabetes management [2]. A pattern analysis conducted by Parkin CG, et al. demonstrated that the utilization of SMBGs allows healthcare providers to identify issues in diabetes management and make rational therapeutic adjustments based on objective data [3].However, the limitations facing the utilization of diabetes monitoring apps are the reliance on patients inputting data manually, which may reduce adherence, as noted by Ciemins E, et al [4]. It must be noted that further studies are needed to determine the use of applications to reduce microvascular and macrovascular complications of diabetes [2, 4].Lastly, a recent review conducted via iMedicalApps evaluated the use of Diabetes Buddy in managing patients with Adult Type 1 Diabetes. The study investigated the utilization of the application as an adjunctive tool to help manage diabetes. Results demonstrated that there was a significant decrease in A1c in the intervention group over the control group who did not use the app [5].
การแปล กรุณารอสักครู่..